{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-035634","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.534712+00:00","generated_at":"2026-05-17T06:03:32.384621+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ionis reports positive pivotal study results for zilganersen in Alexander disease; NDA planned Q1 2026","bullets":["Primary endpoint met: gait speed improved 33.3% vs control (p=0.0412) at week 61 in 50 mg cohort.","No approved disease-modifying treatments for Alexander disease; first investigational drug to show positive impact.","Safety profile favorable: most adverse events mild/moderate; SAEs numerically lower in zilganersen arm.","NDA submission to FDA targeted for Q1 2026; evaluating U.S. Expanded Access Program."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-035634","json":"https://secwatch.observer/filing/0001140361-25-035634.json","markdown":"https://secwatch.observer/filing/0001140361-25-035634.md","text":"https://secwatch.observer/filing/0001140361-25-035634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125035634/0001140361-25-035634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125035634/ef20055880_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:03:32.384621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}